Prostate Cancer DREAM Challenge

Using the proven DREAM methodology, Project Data Sphere, LLC (PDS) and Sage Bionetworks conducted the Prostate Cancer DREAM Challenge (PCDC) in 2015. The PCDC used curated data from four phase III trials studying metastatic Castrate Resistant Prostate Cancer (mCRPC) from the Project Data Sphere platform.

Prostate Cancer DREAM Challenge

Participants were asked to predict overall survival for mCRPC using patients clinical variables at baseline, and to predict treatment discontinuation for mCRPC patients treated with docetaxel due to adverse events. More DREAM solvers participated in the PCDC than any other DREAM Challenge to date, and the best performing teams produced exciting improvements on existing prognostic models.

PDS is excited to make the PCDC data available to the entire research community for further research during the Public Leaderboard period. After registering for access, users can access the PCDC data, develop their own prognostic models, and submit those models on the PCDC Synapse page for scoring.